Oragenics, Inc. Announces the Early Exercise of Warrants
03 Mars 2008 - 7:12PM
Marketwired
ALACHUA, FL , a biotechnology company focused primarily on
infectious diseases, announced today that a total of 3,386,364
warrants issued to investors who participated in the August 2007
investment round in Oragenics have been exercised early at a price
of $0.44. This early exercise resulted in aggregate proceeds to the
Company of $1.49 million. The Company plans to use the proceeds of
this warrant exercise to support its lead product development
programs.
About Oragenics
Oragenics, Inc. is a biopharmaceutical company with a pipeline
of proprietary technologies. The Company has a number of products
in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases.
Our core pipeline includes products and supporting platform
technologies for use in the treatment and diagnosis of bacterial
infections.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect Oragenics' current views with respect to
future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-KSB and quarterly report on Form 10-QSB, and
other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.
Contact: Oragenics, Inc. Dotti Delfino 386-418-4018 X232
www.oragenics.com
Oragenics (AMEX:ONI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oragenics (AMEX:ONI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Oragenics, (American Stock Exchange): 0 recent articles
Plus d'articles sur Oragenics, Inc.